JNJ-10198409

JNJ-10198409 is a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC50=2 nM) . It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM) [1][2].

Product Specifications

CAS Number

[627518-40-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PDGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/jnj-10198409.html

Purity

99.58

Solubility

DMSO : 83.33 mg/mL (ultrasonic)

Smiles

COC1=CC2=C(C=C1OC)CC3=C2NN=C3NC4=CC=CC(F)=C4

Molecular Formula

C18H16FN3O2

Molecular Weight

325.34

Precautions

H302, H315, H319, H335

References & Citations

[1]D'Andrea MR, et al. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther. 2005 Aug;4 (8) :1198-204.|[2]Ho CY, et al. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl) phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J Med Chem. 2005 Dec 29;48 (26) :8163-73.